Oramed Pharmaceuticals Inc.
ORMP
$2.74
-$0.01-0.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 50.41% | -14.06% | 29.39% | 1.09% | -56.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.43% | -20.61% | 119.45% | -7.27% | 6.77% |
| Operating Income | 21.43% | 20.61% | -51.92% | 7.27% | -6.77% |
| Income Before Tax | 421.20% | 21.18% | -560.10% | -173.58% | -463.61% |
| Income Tax Expenses | 876.35% | -107.71% | -- | -- | -- |
| Earnings from Continuing Operations | 346.35% | 44.07% | -598.17% | -176.71% | -498.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -73.91% | 250.00% | -- | -75.00% | -62.90% |
| Net Income | 346.67% | 44.25% | -597.53% | -176.40% | -508.91% |
| EBIT | 21.43% | 20.61% | -51.92% | 7.27% | -6.77% |
| EBITDA | 21.11% | 20.19% | -53.82% | 6.80% | -6.97% |
| EPS Basic | 341.61% | 41.53% | -593.09% | -176.12% | -501.88% |
| Normalized Basic EPS | 22.95% | 32.93% | -69.48% | 22.86% | 40.65% |
| EPS Diluted | 335.42% | 40.91% | -605.32% | -181.22% | -502.26% |
| Normalized Diluted EPS | 25.00% | 33.13% | -72.28% | 20.83% | 40.65% |
| Average Basic Shares Outstanding | 2.10% | 1.91% | 0.96% | 0.36% | 1.11% |
| Average Diluted Shares Outstanding | 4.59% | 2.45% | -0.81% | -2.07% | 1.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |